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Abstract 
Niacin can reduce vascular disease risk, but its mechanism of action is controversial, 
and may not be dependent on systemic lipid modifying effects. This thesis tested the 
hypothesis that niacin directly improves endothelial cell function under lipotoxic and low 
oxygen conditions, as seen in ischemic conditions during metabolic syndrome, and 
investigated the potential mechanism involved.  Human microvascular endothelial cell 
(HMVEC) survival was reduced by exposure to excess fatty acids under both normoxic and 
low oxygen conditions. Angiogenic function, as determined by tube formation on Matrigel, 
was impaired during fatty acid overload under either normoxic or low oxygen conditions.  
These effects were prevented by pretreatment with niacin, at a pharmacologically relevant 
dose, and appeared to be mediated by the niacin receptor, GPR109A, which we have recently 
shown to be expressed on human endothelial cells.  In a mouse model of diet-induced obesity 
and metabolic syndrome, treatment with niacin improved functional recovery from acute 
ischemic injury. In conclusion, niacin improved HMVEC angiogenic function under 
lipotoxic and hypoxic conditions, effects that may translate to improved recovery from 
peripheral ischemia in vivo. 
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Chapter 1  
1 Introduction 
1.1 Obesity and Metabolic Syndrome, and their association 
with Ischemic Vascular Disease 
Metabolic syndrome has become a highly prevalent complication of obesity 
globally, and its occurrence is continuing to increase. Since 1980, worldwide obesity has 
doubled. In 2008, more than 1.4 billion adults were overweight (World Health 
Organization, 2013). The increase in prevalence of metabolic syndrome corresponds most 
closely to the increase in consumption of lipogenic foods over this time frame. The 
composition and caloric content of commercially manufactured meals, and their relatively 
low cost have encouraged consumption of larger portions. (Sturm & An, 2014; Unger & 
Scherer, 2010). 
Components of metabolic syndrome include elevated blood pressure, 
dyslipidemia, increased blood glucose, and central (visceral) obesity. Various diagnostic 
criteria for metabolic syndrome have been proposed by different organizations over the 
past decade. The International Diabetes Federation (IDF) and the American Heart 
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) have recently 
defined the criteria and cut-offs for metabolic syndrome. In order to be diagnosed with 
metabolic syndrome, one must have at least 3 of the 5 following criteria: elevated waist 
circumference, elevated triglycerides greater than 1.7 mmol/L, reduced high-density 
lipoprotein (HDL) less than 1.0 mmol/L, elevated blood pressure with systolic ≥130 
and/or diastolic ≥85 mm Hg, or elevated fasting glucose of ≥100 mg/dL (Alberti et al., 
2009). Whether central obesity (elevated waist circumference) is considered an absolute 
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requirement for diagnosis varies between proposed criteria.  Obesity is defined as 
abnormal or excessive fat accumulation that may impair health, and is largely caused by 
an energy imbalance between calories consumed over calories used (World Health 
Organization 2013). In order to be considered obese, body mass index (BMI = weight 
[kg]/height
2
 [m
2
]) must be greater than 30 kg/m
2
. 
During obesity, excessive adipose tissue accumulation is directly related to 
increased adipocyte number and size. The role of adipose tissue in physiology and 
pathophysiology is complex since it is involved not only in lipid synthesis and storage, but 
also in secretion of different molecules. Adipocytes store excess lipids during increased 
fuel (fatty acids and glucose) availability in the form of triglycerides, which can be 
released by lipolysis in the fasted state to provide free fatty acids for energy to other 
organs (Suganami, et al 2012). Adipokines, such as leptin, are released in parallel to 
adipocyte expansion. Leptin acts on the hypothalamus to decrease food intake to limit 
over-nutrition, and can also minimize ectopic accumulation of lipids in cells other than 
adipocytes through leptin-induced fatty acid oxidation (Unger & Scherer, 2010). 
Adipocytes are also known to secrete proinflammatory molecules during obesity, such as 
tumour necrosis factor alpha (TNFα) and monocyte chemoattractant protein-1 (MCP-1) 
(Guilherme et al., 2008). This leads to macrophage infiltration into adipose 
(inflammation), and further contributes to TNF α and MCP-1 production and release 
(Campia et al., 2012). Both TNFα (Hotamisligil, 2003) and MCP-1 (Sartipy & Loskutoff, 
2003) have been shown to induce insulin resistance in rodent models of obesity.  Insulin 
resistance is increasingly recognized to play a pivotal role in the development of 
metabolic syndrome. 
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Adipose tissue inflammation can lead to uncontrolled lipolysis, through the actions 
of TNF on adipocyte lipogenic and lipolytic pathways (Guilherme et al., 2008). The 
liver is sensitive to this increased flux of fatty acids from adipose, and responds with 
increased synthesis of very low density lipoproteins (VLDL) (Sniderman & Cianflone, 
1995; Nikolopoulou & Kadoglou, 2012). Increased VLDL production also results from 
hepatic insulin resistance, as insulin is no longer able to suppress VLDL synthesis in this 
setting (Sparks et al., 2012). With chronic ingestion of lipogenic diets and the onset of 
obesity, increased circulating fatty acids  and VLDL can cause lipids to be stored at sites 
other than adipose tissue, including skeletal muscle, heart, liver, and vasculature (Muoio 
& Newgard, 2006). The different organs affected by this ectopic lipid accumulation 
during obesity and metabolic syndrome can be seen in Figure 1.1. 
Vascular diseases are the most common complications in individuals with obesity 
and metabolic syndrome (Campia et al., 2012; Van Gaal et al., 2006). Elevated plasma 
lipids can cause inflammatory responses in the endothelium and the subsequent 
recruitment of macrophages (Ross, 1999; Libby, 2012). The accumulation of both 
macrophages and lipids within arterial walls can cause atherosclerotic plaques in large to 
medium sized arties (Talayero & Sacks, 2011). The development of plaques can occlude 
arteries, and upon rupture can lead to coronary syndromes or myocardial infarctions 
(Ross, 1999). Extracoronary manifestations of plaques can also occur and cause peripheral 
artery disease (PAD), which is associated with decreased blood flow to the extremities 
and distal tissues. The restriction of blood flow to the periphery causes peripheral 
ischemia and in some severe cases, it can lead to critical limb ischemia requiring 
amputation (Ouriel, 2001; Teodorescu et al., 2013). Metabolic syndrome is associated 
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with higher incidence of ischemic stroke (Chen, et al, 2006), increased ischemic 
myocardial injury and impaired recovery of function after reperfusion (Liu & Lloyd, 
2013), increased peripheral artery disease (Garg PK et al., 2014), and the worsening of 
peripheral ischemia (Gardner AW et al., 2006). 
1.2 Endothelial Damage during Obesity and Metabolic 
Syndrome 
Endothelial cells are a major regulator of vascular health and serve many 
physiological functions. The endothelium is a monolayer of cells covering the vascular 
lumen and plays an integral role in the regulation of vascular tone, platelet activity, 
leukocyte adhesion, thrombosis, vascular wall permeability, vasodilation and constriction, 
and vascular repair (Sena et al., 2013). Endothelial cells are metabolically active and can 
secrete vasoactive regulators such as nitric oxide (NO) (Grover-Páez & Zavalza-Gómez, 
2009), which is the key endothelium-derived relaxing factor involved in the maintenance 
of vascular tone and reactivity. Endothelial cells are also critical for vascular repair and 
regeneration (Imrie et al., 2010). Therefore, in addition to vasodilation, the maintenance 
of endothelial cell capacity for vascular repair and regeneration is recognized as vital to 
the control of vascular disease, the most common complication of obesity and metabolic 
syndrome. 
Endothelial dysfunction was first reported to be associated with obesity in 1996 by 
Steinberg et al. It has since been observed that endothelial dysfunction is also common 
during metabolic syndrome and precedes the development of vascular disease, including 
peripheral ischemia (Campia et al., 2012; Kim et al., 2012; Vita and Hamburg, 2010). 
Clinically, it refers to a decrease in endothelium-dependent vasodilation, characterized by  
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Figure 1.1. Organs affected during obesity and metabolic syndrome. 
During caloric surplus coupled with a sedentary lifestyle, elevated circulating fatty acid 
levels eventually exceed the storage capacity of adipose tissue, resulting in the 
uncontrolled flux of non-esterified fatty acids (NEFAs) into the bloodstream and the 
development of a hyperlipidemic state. Hyperlipidemia causes hepatic insulin resistance, 
which increases hepatic production of VLDL into the circulation. Increased plasma 
concentrations of NEFAs and VLDL result in ectopic lipid accumulation in the pancreas, 
skeletal muscle, cardiac tissue, and the vasculature, causing tissue dysfunction. (Adapted 
from Muoio et al., 2006).   
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decreased NO bioavailability (Brevetti et al., 2008; Symons & Abel, 2013). Bigornia et al. 
(2010) showed that endothelial function was improved with weight loss in obese patients. 
Interestingly, their findings showed that metabolic changes were stronger determinants of 
vascular improvement than degree of weight reduction. This suggested that endothelial 
dysfunction was mediated by metabolic parameters during obesity, rather than by weight 
gain itself. 
The response of endothelial cells to changes in their microenvironment is gradual 
and is dependent on the extent and intensity of the stressors. The endothelium initially 
responds to circulating stressors by modulating constitutive cellular functions, followed 
by endothelial dysfunction, and finally injury (Simionescu, 2007; Kim et al., 2012). 
Continued injury can ultimately lead to cell death, limiting the vascular repair and 
angiogenic functions of the endothelium (Imrie et al., 2010). When insults to endothelial 
cells, such as hyperlipidemia or hyperglycemia, are first presented the two constitutive 
functions of selective permeability and biosynthetic capacity are altered (Simionescu, 
2007). Through a variety of in vivo experiments, it has been previously demonstrated that 
low density lipoproteins (LDL) or VLDL can accumulate in the subendothelium due to 
the altered permeability during obesity, as well as transcytosis of lipoprotein particles 
(Nielsen et al., 1992; Vasile et al., 1989). In conjunction with the change in permeability, 
endothelial cell conversion to a secretory phenotype has been observed, characterized by 
multiple well-developed biosynthetic organelles (Simionescu, 2007). In parallel to 
attaining a secretory phenotype, endothelial cells can also induce their expression of 
selective surface adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-
1), in order to recruit monocytes and mount an inflammatory response (Grover-Páez & 
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Zavalza-Gómez, 2009). Endothelial cell dysfunction is present in the vasculature prior to 
the formation of an atherosclerotic plaque, serving as an earlier marker of vascular disease 
(Verma et al., 2003). 
1.3  Lipotoxicity and Endothelial Cells 
During obesity and metabolic syndrome, elevated circulating triglyceride-rich 
lipoproteins and free fatty acids can lead to lipid accumulation in non-adipose tissues 
(Figure 1.1). In many different cell types, this influences membrane structure, intracellular 
signaling, and energy homeostasis, and can ultimately lead to cell dysfunction and death. 
Collectively, this process is known as lipotoxicity (Brookheart et al., 2009). In all cell 
types, incorporation of fatty acids into triglycerides within cytosolic lipid droplets is the 
first line of defense in response to fatty acid overload (Garbarino & Sturley, 2009).  Cells 
can also oxidize excess fatty acids, to varying degrees, through mitochondrial -oxidation.  
It is only when these metabolic pathways are overwhelmed that lipotoxicity occurs.  
Endothelial cells may be particularly vulnerable to lipotoxicity because they are 
continually exposed to elevated concentrations of triglyceride-rich lipoproteins and free 
fatty acids during metabolic syndrome. Moreover, they are not metabolically programmed 
to process large amounts of lipids because they generate ATP primarily through aerobic 
glycolysis (Dagher et al., 2001; Helies-Toussaint et al., 2006). Pathways involved in 
lipotoxicity in endothelial cells are summarized in Figure 1.2, and are described in greater 
detail in the remainder of this section. 
It has been generally observed that saturated fatty acids have adverse effects on 
cells. In contrast, unsaturated fatty acids are non-cytotoxic and may even protect against  
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Figure 1.2. Roles of mitochondria and the ER in saturated fatty acid overload-
induced cell death.   
During exposure to excess saturated fatty acids, cellular capacities to store them as 
triglycerides (lipid droplets) and to catabolize them through β-oxidation (mitochondria) 
are overwhelmed. The resultant production of ROS, from several potential sources, can 
induce ER stress. Palmitate can also be rapidly incorporated into complex lipids in the ER 
membrane resulting in dramatic impairment of the structure and integrity of the ER.  Both 
oxidative stress and altered ER composition and integrity result in the release of ER 
calcium stores, triggering cell death via mitochondria.
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injury caused by saturated fatty acids. Previous studies in endothelial cells have 
demonstrated that saturated fatty acids can induce apoptosis in a dose dependent manner; 
whereas unsaturated fatty acids do not, and can even stimulate proliferation (Ciapaite et 
al., 2007; Staiger et al., 2006; Brookheart et al., 2009). Palmitate, the most common 
saturated fatty acid in western diets, has been shown to have lipotoxic effects in primary 
endothelial cell cultures and in vivo models (Yamagishi et al., 2002; Lu et al., 2013).  
Oxidative stress due to reactive oxygen species (ROS) accumulation is commonly 
observed during palmitate overload in endothelial cells (Kim et al., 2012). Fatty acid 
induced oxidative stress can occur through protein kinase C (PKC)-dependent activation 
of NAD(P)H oxidase (Inogushi et al., 2000), and through the excess generation of ROS 
by-products of mitochondrial β-oxidation and ATP synthesis.  Cellular levels of these 
ROS are normally controlled by enzymatic scavengers, however, limited or incomplete -
oxidation and altered [NAD
+
]/[NADH] ratios likely contribute to excessive mitochondrial 
ROS production during fatty acid overload (Adam-Vizi & Chinopoulos, 2006). 
Endothelial cell dysfunction resulting from oxidative stress includes decreased NO 
bioavailability, through multiple mechanisms including generation of ONOO- anions 
(Campia et al., 2012). ROS can also activate nuclear factor κB (NF-κB) in endothelial 
cells causing its translocation to the nucleus, and subsequent activation of 
proinflammatory gene expression (de Winther etal., 2005). Thus excess saturated fatty 
acids can trigger dysfunction and death in endothelial cells through cellular generation 
and accumulation of reactive oxygen species (ROS). 
During exposure to excess palmitate, there is an increase in toxic bioactive lipid 
metabolites, particularly ceramide (Symons & Abel, 2013). Ceramide is a lipid second 
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messenger involved in initiating apoptosis in response to stimuli (Brookheart et al., 2009). 
Palmitate is a preferred substrate for de novo ceramide synthesis, and increased de novo 
ceramide synthesis is a result of increased substrate availability (Listenberger et al., 2001).  
The studies of Zhang et al. (2012) revealed that de novo ceramide biosynthesis reduced 
protein phosphatase 2A (PP2A) association with the endothelial nitric oxide synthase 
(eNOS), which led to reduced agonist-stimulated eNOS phosphorylation and NO 
bioavailability in endothelial cells. Ceramide has also been demonstrated to increase 
NADPH oxidase activity and increase ROS production (Zhang et al., 2003). Thus 
palmitate can induce endothelial cell dysfunction and apoptotic cell death through the 
generation of ceramide.  
Saturated fatty acid overload can also induce endoplasmic reticulum (ER) stress 
and cell death in several cell types (Brookheart et al., 2009). Excess palmitate is rapidly 
incorporated into ER membranes, leading to disruption of the ER membrane integrity, ER 
stress, and finally initiation of apoptosis (Borradaile et al., 2006). This phenomenon has 
recently been confirmed in endothelial cells by Lu et al. (2013) by analyzing the 
expression of ER stress markers, including C/EBP homologous protein (CHOP), in 
response to treatment with palmitate. 
1.4 Hypoxia and Endothelial Cells 
Extracoronary manifestations of atherosclerotic plaques can cause PAD, also 
known as peripheral vascular disease (PVD), which is associated with decreased blood 
flow to extremities and distal tissues. Restriction of blood flow to the periphery causes 
peripheral ischemia and in some severe cases, it can lead to critical limb ischemia 
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requiring amputation (Ouriel, 2001; Teodorescu et al., 2013). Loss of endothelial cell 
mediated vasodilation during endothelial dysfunction can also cause ischemia.  
Under normal physiological conditions, endothelial cells mount an angiogenic 
response to hypoxic conditions induced by peripheral ischemia, in an attempt to restore 
blood flow (Manalo et al, 2005; Luo et al, 2012). 
Furthermore, endothelial cells release NO upon exposure to acute hypoxia, which 
plays a major role in the local regulation of vascular smooth muscle tone. However, 
endothelial cell dysfunction decreases endothelium-dependent vasodilation, characterized 
by decreased NO bioavailability (Brevetti et al., 2008; Symons & Abel, 2013). Thus, 
endothelial cell dysfunction may prevent the release of NO for vasodilation, and from 
initiating angiogenesis during hypoxia. 
 An important endothelial response during hypoxia is the activation of transcription of 
many specific genes, regulated by hypoxia inducible factor 1 (HIF-1) (Parternotte et al., 
2008). HIF-1 functions as a master regulator in response to cellular oxygen levels, 
undergoing conformational changes in response to oxygen concentrations (Ho et al., 
2006). There are two subunits, HIF-1α and HIF-1β.  The HIF-1β subunit is constitutively 
expressed and is oxygen independent. In contrast, HIF-1α is oxygen dependent and is 
rapidly degraded during normoxia by the ubiquitin-proteosome pathway (Ho et al., 2006). 
Exposure to low oxygen will inhibit the degradation of HIF-1α, allowing it to accumulate 
and translocate to the nucleus (Gao et al., 2012). Once in the nucleus, HIF-1α 
heterodimerises with HIF-1β to form an active transcription factor. HIF-1 plays a crucial 
role during angiogenesis in response to hypoxia by activating transcription of genes 
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encoding angiogenic growth factors, such as vascular endothelial growth factor (VEGF) 
and angiopoietin 1 (ANGPT1) (Kelly et al., 2003).  
In most cell types, mitochondria respond to altered oxygen levels through changes 
in electron transport chain complex activity (Bhatnager, 2003; Essop, 2007). Under low 
oxygen conditions, the electron transport respiratory chain runs less efficiently and 
cytochrome C has reduced capacity to trap oxygen. This phenomenon alters cellular redox 
potential and increases ROS production (Paternotte et al., 2008).  Links between 
mitochondrial ROS generation and HIF-1 regulation during hypoxia have also been 
suggested (Cash et al., 2007; Pung et al., 2000). Hypoxia also diminishes cellular capacity 
for fatty acid β-oxidation, thereby limiting clearance of excess fatty acids through this 
metabolic pathway. Taken together, this suggests that combined hypoxia and fatty acid 
excess, as might occur during peripheral vascular disease associated with obesity and 
metabolic syndrome, would impair endothelial cell angiogenic function. 
1.5 Regulation of Lipid Metabolism by Niacin 
1.5.1  GPR109A-independent Effects 
Niacin (nicotinic acid, vitamin B3) is one of the oldest lipid-lowering drugs and 
has been clinically used for decades since its discovery in 1955 (Altschul et al., 1995). 
Pharmacologic doses of niacin reduce all proatherogenic lipids and lipoprotein particles, 
including total cholesterol, triglycerides, VLDL, and LDL (Kamanna et al., 2013). Niacin 
also raises HDL cholesterol, thus improving overall lipid profiles in dyslipidemic patients, 
particularly those with the dyslipidemia characteristic of metabolic syndrome (elevated 
triglycerides and low HDL) (Creider et al., 2012; Goldberg et al., 2000). However, 
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clinical use of niaicin is often avoided due to its cutaneous flushing effect which, although 
not harmful, limits patient compliance.  
Several mechanisms have been proposed to explain the action of niacin to improve 
lipid profiles. The liver is one of the many target tissues for niacin. Using the human 
hepatocyte cell line (HepG2), Kamanna et al. (2013) recently demonstrated that niacin 
directly and noncompetitively inhibited microsomal diacylglycerol acyltransferase 2 
(DGAT2), a key enzyme that catalyzes the final reaction in triglyceride synthesis. 
Inhibiting DGAT2 decreases triglyceride synthesis and thus its availability for VLDL 
assembly, resulting in decreased production of VLDL and its catabolic product, LDL 
(Creider et al., 2012). In support of this concept, Hu et al. (2012) showed in a small study 
in 39 dyslipidemia patients that extended- release niacin (2 g/day) treatment for 23 weeks 
significantly decreased liver fat content. Furthermore, they were also able to show that 
polymorphisms of DGAT2 were associated with a smaller reduction in liver fat content 
after niacin treatment.  
As mentioned above, niacin also improves the lipid profile of dyslipidemic 
patients by increasing HDL. In the liver, niacin selectively inhibits the expression of 
hepatocyte β-chain ATP synthase, the hepatocyte HDL catabolism receptor, leading to 
reduced hepatic removal of HDL protein (Zhang et al., 2008). This results in increased 
apoAI HDL subfractions and helps drive reverse cholesterol transport (Villines et al., 
2012). Niacin has also been shown to decrease cholesteryl ester transfer protein (CETP), 
which exchanges triglycerides in VLDL and LDL particles for cholesteryl esters in HDL 
particles (Van Der Hoorn et al., 2008). As plasma HDL levels are inversely associated 
with triglyceride levels, the reduction of triglyceride and CETP activity by niacin is 
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suggested as an indirect route to increase HDL cholesterol levels (Creider et al., 2012). 
Additionally, niacin may improve reverse cholesterol transport efficiency by increasing 
the expression of peroxisome proliferator-activated receptor γ (PPARγ) and ABC 
transporter A family member 1 (ABCA1) cholesterol transporters in macrophages and 
monocytes (Villines et al., 2012). 
1.5.2  GPR109A-dependent Effects 
Some of the effects of niacin are mediated through a cell surface receptor, 
GPR109A. This seven-transmembrane G-protein coupled receptor has a high affinity for 
niacin and was discovered by three separate groups in 2003 (Wise et al., 2003; Soga et al., 
2003; Tunaru et al., 2003). GPR109A is endogenously activated by hydroxycarboxylic 
acids and couples to Gi-type G-proteins, resulting in inhibition of adenylyl cyclase 
(Ahmed et al., 2009). Since its discovery, it has been shown to be expressed by several 
tissues including adipose, intestinal epithelium, epidermal Langerhans cells, and several 
immune cell types (Ahmed et al., 2009). The adverse flushing side-effect of niacin has 
been reported to be a result of activation of GPR109A in Langerhans cells, leading to 
release of prostaglandins (Benyo et al., 2005). However, important to this thesis, 
GPR109A expression has not been previously reported in vascular endothelial cells. 
Activation of GPR109A inhibits cyclic adenosine monophosphate (cAMP) 
accumulation in adipose tissue and mediates the anti-lipolytic effects of niacin in vivo 
(Tunaru et al., 2003). Decreased cAMP levels result in reduced hydrolysis of triglycerides 
to free fatty acids in adipose tissue (Offermanns, 2006), therefore limiting the substrate 
availability of fatty acids for hepatic triglyceride synthesis and subsequent assembly of 
VLDL and LDL. This phenomenon was further confirmed by Zhang et al. (2005). The  
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Figure 1.3. Mechanisms of action of niacin in regulating plasma lipids. 
Niacin decreases LDL levels by: directly inhibiting DGAT2, a key enzyme for 
triglyceride synthesis; binding to receptor GPR109A to decrease lipolysis and free fatty 
acid flux to the liver. Niacin increases HDL levels by: selectively inhibiting hepatic ATP 
synthase β-chain, leading to reduced HDL removal; decreasing hepatic and plasma CETP, 
which exchanges triglycerides in VLDL and LDL particles for cholesteryl esters in HDL 
particles; increasing the expression of PPARγ and ABCA1 cholesterol transporters to 
improve reverse cholesterol transport. (Adapted from Creider et al., 2012)  
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combined inhibitory effects of niacin on DGAT2 in the liver and on lipolysis (via 
GPR109A) in adipose, results in decreased circulating VLDL and, subsequently, 
decreased exchange of triglycerides with HDL, leading to elevated levels of HDL 
cholesterol (Offermanns, 2006; Creider et al., 2012).  However, a more direct role for the 
GPR109A-mediated effect of niacin in increasing HDL is supported by the fact that other, 
selective GPR109A agonists, such as acipimox also increase HDL cholesterol (Series et 
al., 1990).  
Interestingly, the GPR109A-dependent effects of niacin in lipid lowering have 
recently been called into question.  An extensive study with a GPR109A knockout mouse, 
and with agonists of GPR109A, showed that these mice retained the triglyceride and LDL 
lowering, and HDL raising effects of niacin (Lauring et al., 2012). In the same study, 
treatment of dyslipidemic patients with selective GPR109A agonists did not improve their 
serum lipid profiles, but did result in an acute lowering of plasma free fatty acids.  A 
summary of the effects of niacin in regulating plasma lipids is depicted in Figure 1.3. 
1.6 Regulation of Vascular Cell Function by Niacin 
1.6.1  Immune Cells 
Negative outcomes of recent clinical trials (Investigators A-H, 2011; Group HC, 
2013) have undermined the clinical utility of niacin in combination therapies with statins 
in the long-term treatment of dyslipidemia in patients with characteristics of metabolic 
syndrome. Although treatment with niacin, like statins, is associated with worsening of 
blood glucose control in at risk patients (Ong et al., 2014), this adverse effect may be 
independent of activation of the niacin receptor, GPR109A.  In fact, selective activation of 
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GPR109A in patients with type 2 diabetes mellitus has recently been shown to reduce 
serum glucose and noon-esterified fatty acids, and to improve insulin sensitivity, without 
the adverse skin flushing and gastrointestinal disturbances associated with niacin therapy 
(Dobbins et al., 2013). However, despite the disappointing results, niacin monotherapy 
improves vascular health in several patient populations (Creider et al., 2012), including 
those with the dyslipidemia commonly associated with metabolic syndrome (high 
triglycerides and low HDL) (Thoenes et al., 2007). Several studies have also suggested 
that the vascular benefits of niacin may not be dependent on its systemic lipid lowering 
effects (Chai et al., 2013; Digby et al., 2012; Lukasova et al., 2011; Wu et al., 2010).  
Niacin can act on immune cells such as monocytes and macrophages, which 
express GPR109A (Ahmed et al., 2009). Recent evidence suggests that monocytes treated 
with niacin have reduced adhesion to endothelial cells (Tavintharan et al., 2011), and that 
neutrophil infiltration into vessel walls is decreased with niacin (Wu et al., 2010). 
Moreover, activation of GPR109A has been shown to inhibit MCP-1-induced recruitment 
of macrophages to atherosclerotic plaques. Niacin has also been shown to reduce the 
secretion of pro-inflammatory cytokines from macrophages (Lipszyc et al., 2013), and 
knockdown of GPR109A in monocytes results in a loss of the anti-inflammatory effect of 
niacin through the NF-κB pathway (Digby et al., 2012), all of which may further 
contribute to its anti-atherosclerotic effects.  Interestingly, although niacin can act on 
macrophages via GPR109A, it loses its effect on foam cells, as a result of a 
downregulation of GPR109A as macrophages become lipid laden (Chai et al., 2013).  
As mentioned in section 1.5.2, the HDL-raising mechanisms of niacin are 
complex, but may be partially linked to GPR109A-mediated induction of cholesterol 
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efflux from macrophages (Lukosova et al., 2011; Rubic et al., 2004). Niacin can target 
GPR109A to reduce the progression of atherosclerosis by inducing the expression of 
ABCG1 cholesterol transporter and increased cholesterol efflux to HDL in macrophages 
(Lukasova et al., 2011). 
1.6.2  Endothelial Cells 
Several lines of evidence in rodent models exist that support of the concept that 
niacin can improve endothelial cell function independent of correcting dyslipidemia. In 
rats, niacin has been shown to increase angiogenesis in areas of brain ischemia, as shown 
by increased expression of VEGF, ANGPT1, and eNOS, and increased capillary 
formation (Chen et al., 2007). In diabetic mice, niacin has been shown to enhance 
revascularization in areas of peripheral ischemia, independent of changes in plasma lipids 
(Huang et al., 2012). And, in rabbits, treatment with niacin decreased endothelial 
expression of VCAM-1 and MCP-1 (Wu et al., 2010), showing that niacin inhibits 
vascular inflammation and protects against endothelial dysfunction.   
 These findings in rodent models are supported by several human clinical studies.  
Thoenes et al. (2007) measured endothelial function by using ultrasound to evaluate 
endothelium-dependent flow-mediated vasodilation of the brachial artery, and found a 
significant improvement in patients treated with niacin.  Improvements in forearm blood 
flow have also been observed in patients with type 2 diabetes mellitus following niacin 
(Hamilton et al., 2010). Further evidence linking treatment with niacin to decreased 
vascular oxidative stress has recently been shown among healthy middle aged and older 
adults (Kaplon et al., 2014).  With regards to a potential mechanism for this effect, niacin 
has been shown to inhibit ROS production in human aortic endothelial cells (HAEC), 
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accompanied by a reduction in NF-κB activity and inhibition of vascular inflammation 
(Ganji et al., 2009; Vosper, 2009). Finally, recent meta-analyses by Sahebkar (2014) 
confirmed that treatment with niacin improves endothelial function in human populations. 
1.7  Endothelial Cell and Mouse Models of Lipotoxicity and 
Ischemia 
1.7.1 Human Microvascular Endothelial Cells 
Many studies of EC function are based on experimentation in human umbilical 
vein endothelial cell (HUVEC).  Although much has been learned using this cell type, 
these cells are derived from vessels which are rarely affected by the most common 
vascular disorders during metabolic syndrome (Cines et al., 1998).  To most closely 
approximate the cell type which would be involved in revascularization after ischemic 
injury, human microvascular endothelial cell (HMVEC) from normal skin tissue were 
chosen for the experiments presented in this thesis. These cells are derived from a 
vascular bed composed of small vessels which participate in wound healing. 
1.7.2 Diet Induced Obese Mice with Peripheral Ischemic 
Injury 
The most commonly used mouse model for studies of the effects of diet-induced 
obesity is the C57BL/6J mouse.  However, this strain carries 2 mutations in the gene 
encoding nicotinamide nucleotide transhydrogenase (Nnt), which has a role in NAD
+
 
metabolism and the maintenance of mitochondrial function (Sazanov and Jackson, 1994).  
Since niacin is a precursor for NAD
+
 synthesis (Hara et al., 2007), use of this strain and 
may have confounded our study. Therefore, for the in vivo portion of this thesis, the 
129S6/SvEv strain, which does not carry mutations in Nnt, was used.  Importantly, 
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129S6/SvEv mice do become obese, and exhibit many characteristics of metabolic 
syndrome, after being fed a high fat (western) diet for several months. 
1.8 Objectives and Hypothesis 
1.8.1 Rationale 
Obesity and metabolic syndrome are now epidemic worldwide, and are associated 
with greatly increased risk for vascular diseases, including peripheral ischemia. 
Endothelial cells are particularly prone to lipotoxicity, which occurs during obesity and 
metabolic syndrome, because they are not metabolically programmed to process large 
amounts of lipid (Helies-Toussaint et al, 2006; Staiger et al 2006).  During peripheral 
ischemia, endothelial cells mount an angiogenic response to hypoxic conditions in an 
attempt to restore blood flow (Manalo et al, 2005; Luo et al, 2012).  However, hypoxia 
also diminishes cellular capacity for β-oxidation, thereby limiting the clearance of excess 
fatty acids through this metabolic pathway.  
Niacin has been used clinically for decades to lower blood triglycerides and free 
fatty acids, and thereby reduce the risk of vascular disease (Creider et al, 2012).  
However, recent studies indicate  that niacin can improve vascular function and vascular 
regeneration after injury, and that these effects may not be dependent on its systemic lipid 
lowering abilities (Chai et al., 2013; Digby et al, 2012; Huang et al., 2012; Lukasova et 
al., 2011; Tavintharan et al., 2011; Wu et al., 2010). Our lab recently showed that 
supplementation with 10 M niacin (a low, pharmacologically relevant concentration) 
improves human microvascular endothelial cell tube formation on Matrigel during 
exposure to excess palmitate under normoxic conditions (20% O2).  This affect appeared 
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to be mediated in part by the niacin receptor, GPR109A, which was found to be expressed 
by these cells (Hughes-Large et al., 2014, submitted). Whether excess fatty acids cause 
lipotoxicity in endothelial cell during hypoxia, and whether niacin can improve 
endothelial cell angiogenic function under these conditions, in vitro and in vivo, is 
unknown. 
1.8.2 Hypothesis 
Microvascular endothelial cell angiogenic function during hypoxia will be impaired under 
conditions of lipid overload, and may be improved by treatment with niacin. 
1.8.3 Objectives 
The specific objectives of this thesis were to: 
1)  Determine the effect of excess fatty acids on microvascular endothelial cell survival 
and angiogenic function under hypoxic conditions in vitro. 
2)  Determine whether niacin can improve microvascular endothelial cell angiogenic 
function under hypoxic and lipotoxic conditions in vitro. 
3)  Determine whether niacin can improve functional recovery after femoral artery 
ligation and excision in a mouse model of obesity and metabolic syndrome. 
1.8.4 Relevance to Disease 
Endothelial dysfunction is an important initial step in the development of vascular 
complications during obesity and metabolic disease, and the maintenance of endothelial 
cell function opposes the development of vascular disease (Verma et al., 2003; Xu and 
Zou, 2009). Recent studies showed niacin to improve vascular function, independent of 
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systemic lipid lowering. Determining whether niacin can improve human microvascular 
endothelial cell function during lipotoxicity, and by what mechanism, may be important 
steps in determining further clinical applications of this drug. The work described in this 
thesis could have implications for the use of niacin as a treatment for ischemic 
microvascular complications during metabolic disease. 
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Chapter 2  
2 Methods 
2.1 Cell Culture and Treatments  
Primary human microvascular endothelial cells (HMVEC) were utilized for all in 
vitro experiments.  HMVEC, from normal skin tissue of adult donors, were obtained from 
Lonza and cultures were maintained in Medium 199 (Invitrogen) supplemented with 
EGM-2-MV SingleQuots (Lonza), on 100 mm culture dishes, at 37°C and 5% CO2. 
Growth medium was changed every 2-3 days, and cells were subcultured at 80% 
confluence. For all experiments, cells were used between passages 4 and 10. 
Fatty acids were used at concentrations of 0.5 mM palmitate, 0.5 mM oleate, or 
0.5 mM of a combination of palmitate and oleate  (1:1 ratio). Stock solutions of 20mM 
palmitate or 20 mM oleate were prepared by saponification using 0.1 M NaOH and 
incubation at 70°C for 30 min.  Fatty acid stock solutions were complexed with fatty acid 
free 30% bovine serum albumin (BSA) (Sigma) at a molar ratio of 2:1 (fatty acid to BSA). 
Growth medium, supplemented with EGM-2-MV SingleQuots (Lonza), was added to 
reach a final fatty acid concentration of 0.5 mM (Borradaile et al, 2006). All fatty acid 
containing experimental media were warmed to 37
o
C for a minimum of 30 min prior to 
use, to ensure equilibrium between albumin and fatty acids.  Medium, with EGM-2-MV 
SingleQuots (Lonza), supplemented with BSA alone was used as a control. The 
concentrations of fatty acids used reflect the high physiological to pathophysiological 
concentrations observed during metabolic syndrome, obesity and type 2 diabetes mellitus 
24 
 
(Soriguer et al., 2009). The 1:1 ratio of palmitate and oleate is similar to the ratio of 
saturated and unsaturated fatty acids in typical Western diets (Staiger et al., 2004). 
For experimental conditions which included niacin, media were supplemented 
with 10 µM niacin (Fluka BioChemika).  This concentration of niacin reflects average 
plasma concentrations achieved following pharmaceutical dosing (Menon et al., 2007).  
For addition to media, niacin was dissolved in cell culture grade water at room 
temperature. Cell culture grade water was added as a vehicle control where required. Cells 
were pre-treated for 24 h with niacin, followed by re-addition of niacin during 
experimental incubations.  
For in vitro experiments involving hypoxic conditions, oxygen concentrations 
were lowered to 2% by displacement with nitrogen in a CO2/O2 incubator (Panasonic). 
Temperature and CO2 were maintained at 37
o
C and 5%, respectively. Re-oxygenation 
treatments were achieved by incubating cells for 24 h in hypoxic conditions, followed by 
a further 24 h in normoxia (20% oxygen). 
2.2 Palmitate Oxidation 
HMVEC were seeded overnight, in duplicate, at 75,000 cells per well in a 24-well 
plate. Two wells were left without cells, in order to measure background radioactivity. 
Prior to the addition of radioisotope, growth medium was removed and cells were washed 
with warm phosphate buffered saline (PBS). Growth medium containing either DMSO 
(vehicle control) or 200µM etomoxir, a carnitine palmitoyl transferase I (CPT1) inhibitor, 
was added, followed by addition of 
3
H-palmitate complexed to BSA to yield 2.0 µCi/mL 
3
H-palmitate in 100 µM palmitate. Cells were then incubated for 1 h at 37°C. Culture 
25 
 
plates were subsequently placed on ice and media were removed to individual glass test 
tubes. Unreacted fatty acids were extracted from media by 4 washes with hexane. 
Aliquots of the aqueous layers were transferred to scintillation vials for counting. Cell 
proteins were dissolved in 1 N NaOH, and then neutralized with 1 N HCl for 
measurement of total cell protein.  Counts measured represented the amount of 
3
H-
palmitate oxidized to 
3
H-H2O, and were expressed per mg of cell protein.   This protocol 
was modified from Borradaile and Pickering, 2009. 
2.3 Cell Viability 
A Dead Cell Apoptosis Kit (Invitrogen) was used to assess HMVEC apoptosis and 
cell death, by staining with Alexa Fluor 488 annexin V and propidium iodide respectively, 
followed by flow cytometry. Cell staining was performed according to the protocol of the 
manufacturer (Molecular Probes). Following cell culture incubations, as indicated, cells 
were washed in cold PBS and harvested with trypsin-EDTA. Cell samples were 
resuspended in 200 µL annexin V binding buffer at a concentration of approximately 
1×10
6
 cells/mL. A working solution of 100µg/mL of propidium iodide was prepared in 
Annexin V binding buffer. Annexin V and propidium iodide working solution were added 
to each cell sample. Unstained and single stained (either annexin V or propidium iodide) 
control cell samples were prepared at the same time, to facilitate the adjustment of flow 
cytometer settings. Samples were analyzed by flow cytometry (London Regional Flow 
Cytometry Facility, Robarts Research Institute, Western University). Fluorescence was 
measured at 530nm and >575 nm using 488 nm excitation. Cell populations were gated on 
an unstained control and voltages were set with single stained controls. Apoptotic cells 
were defined as annexin V positive and propidium iodide negative. Late apoptotic and 
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necrotic cells were defined as both annexin V and propidium iodide positive. Live cells 
were negative for both annexin V and propidium iodide.  
2.4 Growth Rate 
HMVEC were grown to 80% confluence in 100mm dishes. HMVEC were 
harvested with trypsin-EDTA and then were plated at a known density of 2500 cells/cm
2
 
or 24,000 cells per well in a 6-well plate under various conditions for 48 h, as indicated. 
Cells were then harvested with trypsin-EDTA and counted with a hemocytometer. 
Population doublings were calculated using the following equation: log10(number of cells 
harvested) – log10(number of cells seeded) × (log102)
-1
. 
2.5 Tube Formation 
Prior to assessing tube formation, HMVEC were plated at 80% confluence in a 6-
well plate. Cells were pre-treated for 24 h with niacin at varying oxygen levels, as 
indicated. Matrigel
TM
 Basement Membrane Matrix (BD Biosciences) was thawed on ice 
overnight at 4
o
C, and subsequently added to pre-chilled 24-well plates (200 L per well).  
The plate was incubated for 30 min at 37°C to solidify the Matrigel before plating the 
cells. In order to prepare the cells for plating, HMVEC were harvested with EDTA-trypsin 
and resuspended in fatty acid supplemented media to a concentration of 3.75-5.0 ×10
5
 
cells/mL, with or without the addition of niacin, as indicated.  Prepared cell suspensions 
were dispensed (200 µL per well) onto Matrigel-coated wells. Plates were incubated for a 
further 18 h, at the indicated oxygen concentrations, to allow HMVEC capillary tube 
formation. Resulting tubes were visualized by light microscopy using an Olympus IX71 
microscope. For each well, three fields of view were imaged, and total tube length per 
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field of view was quantified using ImageJ. A tube was defined as a multicellular 
elongated structure stretching between branch points, and having a width approximately 
large enough along its entire length to permit the passage of an erythrocyte (~8µm). This 
protocol was modified from Borradaile and Pickering, 2009. 
2.6 siRNA Transfection 
Prior to transfection, HMVEC were seeded at 60% confluence on a 6-well plate. A 
Cy3 labeled control siRNA (Locus ID 338442, Ambion AM6421) or one of three siRNA 
targeted against GPR109A (Silencer Select Clone IDs s50342, s5033, s50344, Ambion) 
were transfected into HMVEC using Lipofectamine RNAiMAX (Life Technologies).    
For preparation of transfection reagents, 3µL of 10 µM siRNAs were diluted in 150 µL of 
Opti-MEM medium (Life Technologies). Separately, 9 µL of Lipofectamine RNAiMAX 
reagent were also diluted in Opti-MEM medium. Diluted siRNAs were added to the 
diluted Lipofectamine RNAiMAX reagent (1:1 ratio) and incubated for 5 min at room 
temperature. siRNA-lipid complexes were added to the pre-seeded HMVEC cultures, and 
cells were subsequently incubated for 48 h, followed by treatment for 24 h with or without 
niacin, as indicated. HMVEC were then harvested and used for tube formation assays, as 
described in Section 2.5.   
Transfection efficiency at 24 h, in cells transfected with control Cy3 labeled 
siRNA, was estimated to be 80% by fluorescence microscopy.  Knockdown of GPR109A 
protein was confirmed by immunoblotting (as described in Section 2.7) at 72 h.  This time 
point matched the plating of corresponding tube formation assays. 
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2.7 Immunoblotting 
Whole cell lysates were prepared by incubation for 20 min on ice with RIPA 
buffer (Sigma), supplemented with protease inhibitors (Roche). Lysates were centrifuged 
for 2 min at 16,000 ×g to eliminate insoluble material. Total cellular protein was 
determined using a Bicinchonic Acid (BCA) protein assay kit (Thermo Scientific). 
Depending on the protein of interest, 30-50 µg of total cell protein were diluted with 
Laemmli sample buffer containing β-mercaptoethanol. Samples were heated to 95°C for 5 
minutes. Protein samples were resolved by 10% SDS-polyacrylamide gel electrophoresis 
(PAGE) and transferred to a 0.45 µm PVDF membrane using a semi-dry transfer 
apparatus (Thermo Scientific). Membranes were subsequently incubated in 1% blocking 
buffer (Roche) for 1 h at room temperature, followed by an overnight incubation at 4°C 
with a 1:600 dilution of anti-GPR109A rabbit polyclonal antibody (Abcam). After three 5 
min washes with Tris buffered saline containing Tween-20, a 1:5000 dilution of 
horseradish peroxidase (HRP)-conjugated polyclonal anti-rabbit secondary antibody 
(Santa Cruz Biotechnology) was added for 1 h at room temperature. Membranes were 
again washed 3 times for 5 min, followed by incubation for 1 min with Enhanced 
Chemilumnisence Reagent (Roche) and exposure to film. Consistency of protein loading 
was determined by  overnight incubation with a 1:5000 dilution of anti-GAPDH mouse 
polyclonal antibody (Enzo), followed by a 1 h incubation with 1:5000 dilution of HRP-
conjugated polyclonal anti-mouse antibody (Santa Cruz Biotechnology) at room 
temperature. Bands for GPR109A and GAPDH were detected at 42 and 37 kD 
respectively, by comparison to Precision Plus Protein All Blue Standards (Biorad). Bands 
were quantified by densitometry using Quantity One 1-D Analysis Software (Biorad). 
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2.8 Mice 
In order to induce characteristics of metabolic syndrome, five week old male 
129S6/SvEv mice (Taconic) were fed western diet containing 42% of calories from 
animal fat (Harlan Teklad) ad libitum for 15 weeks. Control mice were maintained on 
chow diet with 4% of calories from fat (Harlan Teklad).  
After 15 weeks of control or western diet, mice underwent right femoral and 
saphenous artery ligation, followed by complete excision of the femoral artery. Surgery 
was done above and below the profunda femoris artery with 6-10 silk sutures. Control and 
obese mice were randomized into 3 groups for subsequent treatment with vehicle (saline) 
or niacin. For 14 days following surgery, mice received once daily intra-peritoneal (i.p.) 
injections of vehicle or niacin (50 mg/kg).  
Recovery of hind limb function was assessed on post-surgery days 4, 9, and 15 by 
gait analyses using a Catwalk system (Noldus) to observe paw contact time and intensity 
(Frontini et al., 2011). The Catwalk system was located in at the Neurobehavioural Core 
Facility at Robarts Research Institute, Western University.  
At sacrifice (day 16), blood and tissues (liver, adipose) were harvested and tibialis 
anterior muscles were isolated. Plasma triglycerides and cholesterol were determined by 
enzymatic, colorimetric assays with reagents from Roche Diagnostics. Blood glucose was 
determined with an Ascensia Elite glucometer (Bayer) and plasma insulin was measured 
using a mouse ultrasensitive insulin enzyme-linked immunosorbent assay (ELISA) (Alpco 
Diagnostics). Plasma liver enzymes (ALT and AST) were measured at the London Health 
Sciences Centre Core Laboratory.  Total weights of liver and adipose were measured, and 
30 
 
liver cholesterol and triglycerides were determined by enzymatic, colorimetric assays 
(Roche Diagnostics and Wako Diagnostics). All plasma and tissue biochemical 
measurements, with the exception of plasma ALT and AST, were performed through the 
Metabolic Phenotyping Laboratory in Robarts Research Institute, Western University.  
Tibialis anterior muscles were immersed in zinc fixation buffer and embedded in 
paraffin. Cross-sections 5µm thick were sliced with a microtome (Leica), and were 
analyzed after double immunostaining for CD31 and smooth muscle α-actin. The anti-
body sources were from rats (LEW) and mouse clones 1A4 respectively, with 
hematoxylin as a counter stain. Vessel density and smooth muscle α-actin positive vessels 
were quantified in 12 high powered (x20 objectives) fields at each of three equally spaced 
sectioning planes of the tissues (van der Veer  et al.,2005), using ImageJ. Stained tissue 
sections were imaged using an inverted Olympus BX51 microscope. 
2.9 Statistics 
Statistical analyses were performed using either a one-way ANOVA followed by 
Tukey’s post hoc test or a two-way ANOVA followed by a Bonferroni’s post hoc test. 
Differences in means were considered statistically significant when p < 0.05. GraphPad 
Prism version 5.0 software was used for all statistical analyses and generation of graph. 
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Chapter 3  
3 Results 
3.1 HMVEC fatty acid oxidation and cell survival are 
reduced under lipotoxic and hypoxic conditions 
During hypoxia, cells limit fatty acid -oxidation to conserve oxygen (Bhatnagar, 
 2003).  Since human endothelial cells have been shown to use fatty acids, to some degree, 
to generate ATP (Dagher et al., 2001), we proposed that low oxygen conditions would 
limit palmitate β-oxidation in HMVEC.   We found that HMVEC β-oxidation of palmitate 
was significantly reduced under hypoxic conditions (2% O2) (Figure 3.1), confirming 
functional hypoxia.  
It is generally known that saturated fatty acids can induce apoptosis in a dose 
dependent manner; whereas unsaturated fatty acids do not, and can even stimulate 
proliferation (Ciapaite et al., 2007; Staiger et al., 2006; Brookheart et al., 2009). Thus, we 
anticipated that the combination of hypoxia and high palmitate would reduce HMVEC 
survival.  To determine whether hypoxia affects cell survival during fatty acid overload, 
HMVEC treated for 24 h with fatty acids, in either normoxia or hypoxia, were stained 
with Annexin V (AnnV), as an indicator of apoptosis, and with propidium iodide (PI), as 
an indicator of  late apoptosis and necrosis (Figure 3.2). Cell staining was analyzed by 
flow cytometry. To approximate conditions which might occur in vessels during ischemia 
and reperfusion in vivo (i.e. hypoxia followed by re-oxygenation and exposure to 
circulating lipids), we also performed experiments in which cells were preinucbated for 24 
h at 2% O2, followed by further 24 h incubation at 20% O2 with the addition of excess 
fatty acids (Figure 3.2D). HMVEC cell death was increased during palmitate overload 
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under hypoxic conditions (2% O2) (Figure 3.2C). Although total cell death was increased 
during palmitate overload (Figure 3.2B-D), there was no significant reduction in cell 
survival in hypoxia relative to normoxia and HMVEC survival appears to not be 
significantly affected by hypoxia alone. 
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Figure 3.1. HMVEC β-oxidation of palmitate is reduced under hypoxic conditions. 
Palmitate β-oxidation was assessed by conversion of 3H-palmitate to water. Cells were 
pre-incubated in normoxic (20% O2) or hypoxic (2% O2) conditions for 24h followed by 
incubation with labelled palmitate complexed to BSA, for 1 h. Tritium radioactivity in 
media and aqueous cell fractions were determined by liquid scintillation counting. 
Etomoxir (200 µM), a CPT1 inhibitor, was used as a negative control. Data are expressed 
as means ± SEM for 5 independent experiments. * p < 0.05 vs. vehicle 20% O2. **p<0.05 
vs. respective vehicle control. 
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Figure 3.2. HMVEC cell death is increased during palmitate overload under hypoxic 
conditions. 
Cells were incubated for 24h with medium containing BSA (control), 0.5 mM palmitate 
(PA), 0.5 mM oleate (OA), or PA + OA (1:1, 0.5 mM), all complexed to BSA (molar ratio 
2:1). Cell survival was assessed by staining with annexin V (AnnV) and propidium iodide 
(PI), with quantification by flow cytometry. Representative dot plots for HMVEC in 
hypoxia (2% O2) are shown (A). Percentages of dead cells (AnnV
+
/PI
+
) and apoptotic 
cells (AnnV
+
) were determined under normoxia (20% O2) (B), hypoxia (2% O2) (C), and 
conditions representative of hypoxia followed by re-oxygenation (24h preincucation at 
2% O2, followed by 24h incubation at 20% O2 in presence of fatty acids; 2% O2  20% 
O2) (D). Data are expressed as means ± SEM for 5 independent experiments. * p < 0.05 
vs. BSA.
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3.2 HMVEC angiogenic function is improved by niacin 
under lipotoxic and hypoxic conditions 
Niacin has been used clinically for decades to lower triglycerides (Kamanna et al., 
2013). However, niacin has also recently been reported to improve endothelial cell 
function independent of correcting dyslipidemia (Huang et al., 2012; Thoenes et al., 
2007), and to increase angiogenesis in ischemic brains of adult male rats (Chen et al., 
2007). Thus, we determined whether niacin would improve HMVEC angiogenic function 
during fatty acid overload and hypoxia, conditions which would be observed in peripheral 
ischemia during metabolic syndrome. 
In normoxia, HMVEC exhibited impaired tube formation on Matrigel after 18 h of 
treatment with growth medium containing saturated fatty acid palmitate, whereas 
treatments with unsaturated fatty acid oleate or combination of palmitate and oleate did 
not significantly impair tube formation (Figures 3.3). Niacin improved HMVEC tube 
formation during fatty acid overload under normoxic conditions (Figure 3.3).  Under low 
oxygen (2% O2) conditions, tube formation was reduced for all control and fatty acid 
treatments (Figure 3.4 vs. Figure 3.3). However, niacin was also able to improve tube 
formation under hypoxic conditions for all control and fatty acid treatments (Figure 3.4). 
In order to approximate ischemic insult followed by re-oxygenation, cells were incubated 
for 24 h in hypoxic conditions, followed by 24 h in normoxia. Niacin was not able to 
significantly improve HMVEC tube formation under these conditions (Figure 3.5). 
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Figure 3.3. Niacin improves HMVEC tube formation during fatty acid overload 
under normoxic conditions.  
Cells pre-treated for 24 h at 20% O2 in culture medium supplemented with either vehicle 
(water) or 10 μM niacin (NA) were seeded onto growth factor replete Matrigel and 
incubated with media containing BSA, 0.5 mM oleate (OA), 0.5 mM palmitate (PA), or 
palmitate + oleate (PA+OA, 1:1 ratio, 0.5 mM) complexed to BSA. Cells were again 
treated with either vehicle or 10 μM niacin, and resulting tube networks were analyzed by 
light microscopy after 18 h incubations at 20% O2 (A). Scale bar represents 100 μm. For 
quantification, total tube lengths were measured in three random fields of view per 
condition (B). Data are expressed as means ± SEM for 5 independent experiments.           
* p < 0.05 vs. Vehicle, BSA, **p < 0.05 vs. Vehicle, PA. 
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Figure 3.4. Niacin improves HMVEC tube formation during fatty acid overload 
under hypoxic conditions. 
Cells were pre-treated and seeded on Matrigel, in the absence or presence of 10 µM 
niacin, as described in Figure 3, but under hypoxic conditions (2% O2). Resulting tube 
networks were analyzed by light microscopy after 18 h incubations at 2% O2 (A). Scale 
bar represents 100 μm.  For quantification, total tube lengths were measured for three 
random fields of view per condition (B). Data are expressed as means ± SEM for 5 
independent experiments. * p < 0.05 vs. vehicle, BSA, **p<0.001 vs vehicle, BSA. 
 
  
43 
 
A   Vehicle   Niacin  
  
 
 
BSA 
 
 
 
OA 
 
 
 
PA 
 
 
 
 
PA+OA 
 
 
B 
  
T
o
ta
l 
 T
u
b
e
  
L
e
n
g
th
 (

m
)
Ve h ic le N A
0
1 0 0 0
2 0 0 0
3 0 0 0
B S A
O A
P A
P A + O A
**
* * *
44 
 
  
45 
 
Figure 3.5. Niacin does not improve HMVEC tube formation during fatty acid 
overload under conditions representative of hypoxia followed by re-oxygenation.   
Cells were pre-treated and seeded on Matrigel, in the absence or presence of 10 µM 
niacin, as described in Figure 3, but under hypoxic conditions (2% O2).  Resulting tube 
networks were analyzed by light microscopy after 18 h incubations at 20% O2 (A). Scale 
bar represents 100 μm.  For quantification, total tube lengths were measured in three 
random fields of view per condition (B). Data are expressed as means ± SEM for 5 
independent experiments. 
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3.3 Partial knockdown of GPR109A diminishes niacin 
induced improvements in tube formation under lipotoxic 
and hypoxic conditions 
The niacin receptor, GPR109A, has been shown to be expressed in several 
different tissues and cell types including, adipocytes, intestinal epithelium, epidermal 
Langerhans cells, and several immune cell types (Ahmed et al., 2009). However, its 
expression has never been reported in endothelial cells. Whether the effects of niacin on 
angiogenic function and revascularization involve activation of this receptor on 
endothelial cells is unknown. 
To begin investigating the mechanism for improved HMVEC tube formation with 
niacin, the effects of niacin on cell proliferation in normoxia and hypoxia were 
determined. The in vitro tube-forming capacity of endothelial cells is a dynamic process 
that can initially involve cell proliferation. However, as shown in Figure 3.6, basal 
proliferation rates are unaltered with niacin treatment under normoxic, hypoxic, or re-
oxygenation conditions.  Furthermore, it was previously shown that niacin does not 
improve cell survival during fatty acid overload (Hughes-Large et al., 2014, submitted), 
and that hypoxia does not further increase cell death under lipotoxic conditions (Figure 
3.2).  Taken together, these data suggest that niacin does not likely act by stimulating cell 
proliferation or cell survival pathways under lipotoxic and hypoxic conditions.   
Our lab has recently shown that HMVEC express GPR109A (Hughes-Large et al., 
2014, submitted).  In the same study, it was also demonstrated that treating HMVEC with 
selective GPR109A agonists, acifran and MK-1903, reproduced the effects of niacin on 
tube formation. To further determine the potential role of the niacin receptor, we used 
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siRNA to knockdown GPR109A.  Relative GPR109A levels were assessed by 
immunoblotting after 72 h incubation (Figure 3.7). GPR109A siRNA 2 exhibited the most 
effective knockdown and was used for all subsequent experiments. After transfection with 
siRNA, HMVEC were seeded onto Matrigel for 18 h to assess tube formation under 
various conditions (Figures 3.8 and 3.9). Partial knockdown of GPR109A diminished 
niacin induced improvements in tube formation in high palmitate (Figure 3.8). Similar, 
but not statistically significant, results were obtained in hypoxia (Figure 3.9).  Tube 
formation, in general, was much lower in transfected cells under hypoxic conditions. 
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Figure 3.6. HMVEC growth rate is unaffected by supplementation with niacin. 
HMVEC were plated at a known density of 2500 cells/cm
2
 in medium containing either 
water (vehicle) or 10μM niacin. Incubation conditions were representative of normoxia 
(20% O2), hypoxia (2% O2), and re-oxygenation (2%  20% O2), as described in tube 
formation assays. Cells were counted and population doublings per day were calculated. 
Data are expressed as means ± SEM for 5 independent experiments 
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Figure 3.7. Targeted knockdown of GPR109A.  
Relative GPR109A levels were assessed by immunoblotting after 72 h incubation with 
control siRNA (Cont), or one of 3 distinct siRNA targeting GPR109A (1, 2, or 3). Upon 
establishing that siRNA2 was most effective, densitometry values were determined for 
GPR109A relative to GAPDH in cells transfected with Control versus siRNA2. Data are 
means ± SEM for 4 independent experiments. * p < 0.05. 
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Figure 3.8. Partial knockdown of GPR109A diminishes niacin induced 
improvements in tube formation in high palmitate, under normoxic condtions.  
Cells were transfected for 72 h with siRNA against either no known gene sequence 
(control) (A) or GPR109A (siRNA 2) (B), followed by treatment for 24 h with vehicle or 
10 µM niacin. Cells were then seeded onto Matrigel in medium containing BSA or 0.5 
mM palmitate, and supplemented again with either vehicle or 10 µM niacin. Resulting 
tube networks were imaged and quantified as described in Figure 3.3 (C). Scale bar 
represents 100 µm. Data are means ± SEM for 3-4 independent experiments. * p < 0.05. 
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Figure 3.9. Effect of partial knockdown of GPR109A on niacin induced 
improvements in tube formation in high palmitate, under hypoxic conditions.  
Cells were transfected for 72 h with siRNA against either no known gene sequence 
(control) (A) or GPR109A (siRNA 2) (B), followed by treatment for 24 h with vehicle or 
10 µM niacin. Cells were seeded onto Matrigel in medium containing BSA or 0.5 mM 
palmitate, and supplemented again with either vehicle or 10 µM niacin under hypoxic 
conditions (2% O2). Resulting tube networks were imaged and quantified as in Figure 3.3. 
Scale bar represents 100 µm. Data are means ± SEM for 3 independent experiments. * p < 
0.05 and **p<0.01 vs Vehicle BSA. 
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3.4 Niacin improves recovery of hind limb function after 
ischemic injury in obese mice with metabolic disease 
The endothelial cell injury and death that occur during hyperlipidemia can limit 
the vascular repair and regeneration (Kim et al., 2012). To assess vascular regeneration 
during metabolic disease in vivo, we used 129S6/SvEv mice with diet induced obesity. 
After 15 weeks of ad libitum feeding of western diet, containing 42% of calories from fat, 
129S6/SvEv mice exhibited characteristics of metabolic syndrome, including increased 
adiposity, hypertriglyceridemia, elevated fasting blood glucose, and hyperinsulinemia 
(Table 1). 
129S6/SvEv mice underwent right femoral artery ligation and excision, followed 
by 14 days of i.p. injections of either vehicle (water) or niacin (50mg/kg). To determine 
functional recovery from hind limb injury, a Catwalk System was used to measure paw 
contact time and intensity during walking on days 4, 9, and 15 after surgery (Figure 3.10).  
Mean paw contact time ratios and contact intensity ratios over these time points are shown 
in Figure 3.10B and C. Mean paw contact time on the day prior to sacrifice was 
significantly increased in mice treated with niacin (Figure 3.10A, D). Mean paw intensity 
for the same day did not show a statistically significant increase following treatment with 
niacin, but a trend was observed (Figure 3.10E). These data suggest that treatment with 
niacin, after ischemic injury, improves recovery of hind limb function in a mouse model 
of metabolic syndrome.   
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Table 1. Characteristics of metabolic syndrome in 129S6/SvEv mice 
Five week old male mice were maintained on chow (4% calories from fat) or western diet 
(42% calories from fat) for 15 weeks, followed by unilateral femoral ligation and excision 
surgery. Mice were maintained for a further 14 days with daily i.p. injections of either 
sterile water (vehicle) or niacin (50 mg/kg). Body weight and blood glucose 
measurements were performed immediately prior to sacrifice (day 15). All remaining 
parameters were determined post-mortem. Data are means ± SEM. Values with different 
lower case letters are significantly different at p<0.05, n=6. 
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Diet (Treatment) Chow (Vehicle) Western (Vehicle) Western (Niacin) 
Body weight (g) 26.0 ± 0.7
a
 32.7 ± 1.3
b
 31.1 ± 0.5
b
 
Epidydimal fat weight (g) 0.365 ± 0.036
a
 1.442 ± 0.091
b
 1.032 ± 0.114
c
 
Liver weight (g)  1.011 ± 0.044 1.107 ± 0.052 1.102 ± 0.044 
Liver triglycerides (mg/g)  13.3 ± 2.0
a
 168.4 ± 12.6
b
 66.9 ± 13.3
c
 
Plasma ALT (U/L) 35 ± 9.3 46.7 ± 9.3 20.3 ± 1.3 
Plasma AST (U/L)  106 ± 16.6 119 ± 19.9 91.2 ± 14.4 
Plasma triglycerides (mmol/L)  0.82 ± 0.04
ab
 0.98 ± 0.05
ac
 0.77 ± 0.06 
bd
 
Plasma free fatty acids (mmol/L)  0.34 ± 0.02 0.30 ± 0.02 0.26 ± 0.02 
Plasma cholesterol (mmol/L)  2.85 ± 0.12
a
 5.24 ± 0.21
b
 3.88 ± 0.09
c
 
Blood glucose (mmol/L) 5.2 ± 0.2
a
 6.3 ± 0.1
b
 5.4 ± 0.4
ab
 
Insulin (ng/ml) 0.37 ± 0.06
a
 0.74 ± 0.04
b
 0.47 ± 0.09
a
 
 
 
  
60 
 
  
61 
 
Figure 3.10. Niacin improves recovery of hind limb function after ischemic injury in 
obese mice with metabolic disease.  
Five week old male mice were maintained on chow or western diet (WD) or chow for 15 
weeks, followed by right hind limb femoral ligation and excision surgery. Mice were 
maintained for a further 14 days on their respective diets with daily i.p. injections of either 
sterile water (vehicle) or niacin (NA, 50 mg/kg). On days 4, 9, and 15 post-surgery, gait 
analyses were performed using a Catwalk system. As mice traversed an illuminated glass 
walkway, the duration (s) of surface contact for each paw was digitally recorded and 
illustrated as contact duration maps. Representative maps over a 1.0 s time frame are 
shown for day 15. Arrows indicate the injured limb. (A). Mean paw contact times (B) for 
each hind limb and contact intensities (C) (3 replicate walks per mouse per day) were 
used to calculate hind limb functional recovery. Normal contact time (B) and intensity 
ratio (C) over time between hind limbs is approximately 1.0. A right limb to left limb 
ratio < 1.0 indicates decreased use of the right hind limb. Contact time (D) and intensity 
(E) for each experimental group are shown for Day 15. Data are means ± SEM for 6 mice, 
*p<0.05 vs WD + NA.  
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Chapter 4  
4 Discussion 
4.1 Summary of Results 
Vascular complications associated with obesity and metabolic disease result in a 
large proportion of the morbidity and mortality that accompanies excessive weight gain. 
Endothelial cell dysfunction precedes the development of vascular diseases such as 
peripheral ischemia (Campia et al., 2012). Thus, there is interest in determining whether 
improving endothelial cell function can improve vascular disease outcomes during 
obesity. Niacin has been reported to have vascular benefits that are independent of its role 
in improving clinical lipid profiles (Chai et al., 2013). However, whether niacin can 
improve endothelial cell angiogenic function during saturated fatty acid overload in 
ischemic conditions, as are observed in the vasculature during obesity, and by what 
mechanism this might occur, is unknown. For this thesis, it was hypothesized that 
microvascular endothelial cell angiogenic function during hypoxia would be impaired 
under conditions of lipid overload, and would be improved by treatment with niacin.  
Although we cannot explicitly exclude the involvement of the lower affinity niacin 
receptors, GRP109B and GPER1, the data presented here suggest that niacin may mediate 
pro-angiogenic effects on endothelial cells through activation of GPR109A.  
The major findings of this thesis are as follows: 1) HMVEC fatty acid oxidation 
and cell survival is reduced under lipotoxic and hypoxic conditions;  2) niacin improves 
HMVEC tube formation under lipotoxic and hypoxic conditions;  3) HMVEC express the 
niacin receptor, GPR109A, and partial knockdown of GPR109A with siRNA diminishes 
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the effects of niacin on tube formation in high palmitate;  4) niacin improves recovery of 
hind limb function after ischemic injury in obese mice with metabolic disease. 
4.2 Niacin and Endothelial Cell Angiogenic Function in 
Hypoxia 
A growing number of reports suggest that niacin can improve vascular function 
directly, independent of its systemic lipid modifying activity, by modulating the activity 
of immune cells and endothelial cells (Chai et al., 2013). In support of this concept, 
studies in rodent models of vascular injury suggest that niacin directly improves vascular 
endothelial function and vascular regeneration (Chen et al., 2007; Huang et al., 2012; Wu 
et al., 2010). Improvements in forearm blood flow have also been observed in patients 
with type 2 diabetes mellitus following niacin (Hamilton et al., 2010). Therefore, we 
determined whether niacin would have similar benefits in endothelial cells during fatty 
acid overload and hypoxia.  Endothelial cells would be exposed to these conditions during 
ischemia vascular disease associated with obesity and metabolic syndrome. 
In response to hypoxia, endothelial cells mount an angiogenic response to low 
oxygen conditions in an attempt to restore blood flow (Manalo et al, 2005; Luo et al, 
2012). Interestingly, our in vitro data suggest that the combination of high fatty acids and 
hypoxia generally impairs tube formation. If this data translates to the human in vivo 
scenario, it may suggest that obese patients with peripheral ischemia may not recover 
blood flow without intervention. Consistent with our previous results (Hughes-Large et 
al., 2014, submitted), niacin is able to rescue HMVEC tube formation under lipotoxic and 
hypoxic conditions. These observations of enhanced angiogenic function with niacin, 
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made under conditions of fatty acid excess and low oxygen, may have implications for the 
use of niacin in obese or metabolic syndrome patients with ischemic vascular disease. 
4.3 Activation of GPR109A and Endothelial Cell Angiogenic 
Function 
Niacin can activate its receptor GPR109A, and this activation has been shown to 
exert beneficial anti-inflammatory and antiatherogenic effects (Digby et al., 2012; 
Lukasova et al., 2011). These effects are largely mediated through activation of the 
receptor in monocytes and macrophages.  
Our recent evidence of GPR109A expression in cultured human primary 
endothelial cells, and in human aortic endothelial cells in situ, was the first of its kind 
(Hughes-Large et al., 2014, submitted).  The improved tube formation elicited by 
exposure of HMVEC to either niacin or the selective agonists, acifran and MK-1903, in 
high palmitate, further supported the concept that activation of GPR109A may have 
beneficial effects on cells of the vasculature (Hughes-Large et al., 2014, submitted).  To 
further investigate the potential role of GPR109A, siRNA was used to knockdown the 
receptor. Partial knockdown of GPR109A diminished niacin-induced improvements in 
tube formation in high palmitate. Interestingly, the efficiency of GPR109A siRNA in 
inhibiting the ability of niacin to improve tube formation was greater than might be 
predicted based on the amount of knockdown detected at the protein level.  There are 
several possible explanations for this observation.  First, it is possible that the GPR109A 
antibody used is not entirely specific, and may also detect GPR109B.  This would result in 
underestimation of the degree of protein knockdown.  However, limited signal (by 
western blot) was obtained with this antibody in HepG2 cells, which appear to express 
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more GPR109B than GPR109A (Hughes-Large et al., 2014, submitted).  Second, 
GPR109A siRNA modestly impaired tube formation under basal conditions compared to 
control siRNA.  When this baseline observation is taken into account, the effect of 
GPR109A siRNA is less dramatic.  Third, it is possible that partial impairment of 
GPR109A signaling is sufficient to block the pro-angiogenic effect of niacin in HMVEC.  
Although the involvement of the lower affinity niacin receptors, GPR109B and GPER1, 
cannot be explicitly excluded, the data presented in this thesis suggest that niacin may 
mediate pro-angiogenic effects on endothelial cells under conditions of metabolic stress 
through activation of GPR109A. 
4.4 Niacin and Functional Recovery in Obese Mice with 
Acute Ischemic Injury 
Data presented in this thesis show that treatment with niacin improved recovery of 
limb function in diet-induced obese mice with hind limb ischemic injury, as assessed 
using a Catwalk system immediately prior to sacrifice (Day 15).  In fact, animals treated 
with niacin may exhibit an improved rate of recovery of limb function (Figure 3.10C).   
To determine whether improved hind limb function was related to 
revascularization or improved tissue architecture in the injured muscle, tibialis anterior 
muscles were harvested at the time of sacrifice, fixed, and stained for markers of 
endothelial cells (CD31) and smooth muscle cells (smooth muscle -actin).  At the time 
of writing of this thesis, tissues from only 3 of the 6 mice per experimental group were 
processed and analyzed.  Initial measures of tissue vessel density and vessel smooth 
muscle investment were inconclusive (Figure 3.11), but analyses are ongoing.  
Interestingly, muscle bundles in mice maintained on western diet and treated with niacin 
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appeared to be generally larger than those of control mice.  Further analyses will require 
H&E staining of muscle sections, followed by counting of regenerating (central nuclei) 
versus necrotic (absent nuclei) myocytes, to determine whether niacin improved muscle 
tissue regeneration in these mice. 
4.5  Future Directions 
The in vivo work in thesis cannot distinguish between niacin receptor-dependent 
and –independent effects on revascularization and recovery of hind limb function.  To 
directly implicate GPR109A in any observed effects of niacin on vascular regeneration, 
hind limb ischemic injury experiments could be conducted in GPR109
-/-
 mice and 
corresponding wild type littermate controls. These mice are commercially available as 
cryopreserved embryos on a 129S6/SvEv background (Taconic), and are known to be 
susceptible to diet induced obesity (Wanders, 2012). Post-surgery treatments with niacin 
or GPR109A agonists, followed by analyses of functional recovery, metabolic parameters, 
and tissue architecture would be performed as described in Methods section 2.8. Although 
the niacin receptor activation has not been studied in endothelial cells, activation of 
GPR109A-associated pathways in other cell types have been linked to improved 
angiogenic potential. Prostaglandin E2, a product of GPR109A-mediated cyclooxygenase 
activation in Langerhans cells of the skin, has been shown to induce angiogenic properties 
in HMVEC (Salecedo et al., 2003). This could possibly contribute to some of the 
observed effects of receptor activation, and could also be investigated further in 
GPR109A
-/-
 mice. 
As mentioned in earlier sections of this thesis, a growing number of reports 
suggest that niacin can improve vascular function independent of its systemic lipid 
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modifying activity by modulating the activity of immune cells (Chai et al., 2013).  Niacin 
treatment in our model resulted in improved systemic metabolic parameters including 
plasma lipids (Table 1).  Therefore, the lipid-lowering effect of niacin cannot be excluded 
as a potential part of the mechanism for improved functional recovery in these mice.  In 
order to further address this issue, a time course study could be performed to determine 
whether functional recovery occurs in niacin-treated mice, prior to any observed reduction 
in plasma lipids.  The possibility that niacin improved inflammation in our model, as has 
been suggested in previous studies (Chai et al., 2013), will be addressed through ongoing 
analyses of tissue sections that have already been obtained.  Sections of tibialis anterior 
muscles will be stained for the presence of macrophages. 
Finally, many human vascular diseases are restricted to specific types of vessels 
(Cines et al., 1998). It would be interesting to expand these findings of this thesis to other 
vascular EC types.  One focus of this future direction could be to determine whether 
GPR109A is expressed on other human endothelial cells types, and to determine the status 
of niacin receptor expression in different disease states in a variety of vascular beds. 
In light of the major findings of this thesis, and the future directions outlined in 
this section, there may be implications for the use of niacin, or a specific activator of 
GPR109A, to improve vascular function in the setting of ischemic vascular complications 
associated with metabolic syndrome. 
 
Figure 3.11. Vessel density of the tibialis anterior muscle of injured right hind limb 
after ischemic injury in obese mice with metabolic disease. 
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Five week old male mice were maintained on either chow or western diet (WD), subjected 
to right hind limb femoral artery excision surgery, and treated for a further 14 days with 
i.p. injections of either sterile water (vehicle) or niacin (NA, 50 mg/kg).  
Photomicrographs were taken of sections of the right tibialis anterior muscles. Zinc-fixed 
sections were immunostained for CD31 (brown, black arrows), to identify endothelial 
cells, and smooth muscle α-actin (red, white arrows), to identify vascular smooth muscle 
cells (A). Scale bar represents 100 µm. For quantification, vessel density (B) and vessel 
smooth muscle investment (C) were measured in 12 random fields of view per muscle. 
Data are means ± SEM for 3 mice. 
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